Demographics and clinical features of 22 patients with MOG-IgG
| Female-to-male ratio | 14:8 |
| Median age at symptom onset (years, range) | 30 (4–50) |
| AQP4-IgG positivity | 1 (4.5%) |
| Median follow-up duration (months, range) | 63 (7–200) |
| Clinical course | |
| Monophasic | 5 (22.7%) |
| Multiphasic | 17 (77.3%) |
| Median EDSS at last follow-up (range) | 2.0 (0.0–7.0) |
| Median number of attacks (range) | 3 (1–16) |
| Diagnosis at last follow-up | |
| Neuromyelitis optica spectrum disorder | 10 (45.5%) |
| Multiple sclerosis | 1 (4.5%) |
| Idiopathic AQP4-IgG-negative optic neuritis | 4 (18%) |
| Idiopathic AQP4-IgG-negative myelitis | 4 (18%) |
| Other demyelinating syndrome | 3 (14%) |
| Clinical phenotype at the onset | |
| O | 8 (36%) |
| M | 6 (27%) |
| B | 5 (23%) |
| Multifocal involvement | 3 (14%) |
| O+M | 2/3 (67%) |
| O+B | 1/3 (33%) |
APQ4-IgG, aquaporin-4 immunoglobulin G; B, brain; EDSS, Expanded Disability Status Scale; M, myelitis; MOG-IgG, myelin oligodendrocyte protein immunoglobulin G; O, optic neuritis.